United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
| Revenue (TTM) | $3.15B |
| Gross Profit (TTM) | $2.72B |
| EBITDA | $1.50B |
| Operating Margin | 42.20% |
| Return on Equity | 19.30% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $72.85 |
| Book Value | $149.97 |
| Price-to-Book | 3.33 |
| Price-to-Sales (TTM) | 6.46 |
| EV/Revenue | 5.78 |
| EV/EBITDA | 10.87 |
| Quarterly Earnings Growth (YoY) | 13.40% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $42.89M |
| Float | $39.21M |
| % Insiders | 2.00% |
| % Institutions | 99.87% |
Volatility is currently contracting
United Therapeutics NASDAQ: UTHR outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share repurchases.
United Therapeutics has declined ~12% since my last review, reducing its market cap to ~$21.1 billion. My previous rating was "buy" based on a compelling 2026 Tyvaso franchise plus upcoming catalysts, reflecting valuation and risk considerations. UTHR's current "buy" investment thesis centers on upcoming PDUFA dates and other catalysts that could drive future growth and re-rate the stock.
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase the company's common stock, for approximately $477.6 million. T.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. “Ralinepag has the potential to make an important difference.
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTHR and any ticker you trade — then tracks every position and per-strategy win rate.
